ALNY : Summary for Alnylam Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
53.25-0.96 (-1.77%)
At close: 4:00PM EDT

52.88 -0.37 (-0.69%)
After hours: 4:55PM EDT

People also watch
BMRNACORSGENACADALXN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close54.21
Open54.29
Bid52.00 x 100
Ask53.80 x 2000
Day's Range52.01 - 54.60
52 Week Range31.38 - 80.11
Volume1,078,496
Avg. Volume1,015,693
Market Cap4.58B
Beta3.51
PE Ratio (TTM)-11.11
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Could Biogen Spinoff Bleed This Biotech In Hemophilia?
    Investor's Business Daily3 hours ago

    Could Biogen Spinoff Bleed This Biotech In Hemophilia?

    Alnylam's fitusiran will pull in $989 million in 2025, but won't launch until 2020 amid competition with Biogen spinoff Bioverativ.

  • American City Business Journals2 days ago

    ​Alnylam CEO’s pay fell nearly 80 percent in 2016

    The CEO of Alnylam Pharmaceuticals saw his compensation drop precipitously in 2016 as the Cambridge biotech lost about half of its market value, according to a federal filing. John Maraganore received about $1.7 million in total compensation in 2016, down from nearly $8.3 million in 2015, a decrease of nearly 80 percent, according to the filing on Friday. The filing shows that Maraganore realized nearly $4.9 million in value by exercising options in 2016.

  • Alnylam's LDL-Lowering Drug Positive in Phase II Study
    Zacks2 days ago

    Alnylam's LDL-Lowering Drug Positive in Phase II Study

    Alnylam Pharmaceuticals, Inc. (ALNY) and its partner The Medicines Company (MDCO) announced positive final results from the phase II study, ORION-1, on their experimental PCSK9 inhibitor, inclisiran.